CT-5252

CT-5252
Clinical data
Other namesCT5252; Methyl-12-bromo-8,9-didehydro-2,3β-dihydro-6-methyl-10,11-secoergoline-8-carboxylate
Drug classSimplified/partial LSD analogue
Chemical and physical data
FormulaC17H21BrN2O2
Molar mass365.271 g·mol−1
3D model (JSmol)
  • COC(=O)C1=CCC(CC2CNc3ccc(Br)cc23)N(C)C1
  • InChI=1S/C17H21BrN2O2/c1-20-10-11(17(21)22-2)3-5-14(20)7-12-9-19-16-6-4-13(18)8-15(12)16/h3-4,6,8,12,14,19H,5,7,9-10H2,1-2H3
  • Key:POWSHADSWSCVJU-UHFFFAOYSA-N

CT-5252 is a tryptamine-like less-rigid analogue of lysergic acid diethylamide (LSD). It is a 10,11-secoergoline; that is, an ergoline in which the covalent bond between the 10 and 11 positions of the ergoline ring system has been broken to unconstrain the structure. The drug produces specific LSD-like behavioral changes in guinea pigs but with only about 1/48th the potency of LSD. It also causes seizures at slightly higher doses than those that cause LSD-like effects. CT-5252 was first described in the scientific literature in 1969. The analogue of CT-5252 with an N,N-diethyl-carboxamide moiety on the tetrahydropyridine ring instead of the carboxylate group (i.e., more analogous to LSD) has also been assessed and described.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.